Zydus Pharms gets three FDA supplement approvals in one week for generic drugs
Three ANDA supplements for mycophenolate mofetil hydrochloride and linezolid were approved by the FDA, dated 2026-07-28 and 2026-07-29.
Zydus Pharms had three supplement approvals recorded this week across two of its approved generic drug applications.
- A REMS-related supplement (SUPPL 10) for mycophenolate mofetil hydrochloride, an injectable formulated at 500MG/VIAL under ANDA204473, was approved with a status date of 2026-07-29.1
- A labeling supplement (SUPPL 5) for linezolid 600MG oral tablets under ANDA206097 was approved with a status date of 2026-07-28.2
- A separate labeling supplement (SUPPL 4) for the same linezolid 600MG tablet under ANDA206097 was also approved with a status date of 2026-07-28.3
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.